Pascolizumab

Pascolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL-4
Clinical data
ATC code	none;
Identifiers
CAS Number	331243-22-2 ;
IUPHAR/BPS	7786;
ChemSpider	none;
UNII	N1IOA09R6A;
	(what is this?) (verify)

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.[2]

References

Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.
Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and Experimental Immunology. 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858.

[2] Clinical trial number NCT00024544 for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" at ClinicalTrials.gov